Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 26

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Long-Term Outcomes After Drug-Induced Liver Injury

Hayashi, Paul H., Bjornsson, Einar S. · 2018 · Current Hepatology Reports

Abstract

Purpose of the ReviewThis review serves to update the reader on emerging data regarding a spectrum of drug-induced liver injury (DILI) outcomes that lie between complete resolution and acute liver failure. Such outcomes can range from mild chronic injury to late liver failure and mortality.Recent FindingsSeveral large registries are maturing with large numbers of DILI cases thus shedding light on outcomes including chronic injury and late fatality. We cover definitions commonly used to describe resolution versus chronic injury and mortality due to DILI. We look at rates of occurrence for these different outcomes in major registries. Three specific types of chronic DILI that are illustrative but also easily missed by clinicians are also described.SummaryA small but important proportion of DILI cases do not resolve, going on to develop chronic injury and even liver failure. Defining and recognizing these cases is a challenge because DILI is rare, and chronic injury rarer still. Large registries are beginning to define these previously overlooked long-term outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11901-018-0411-0

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 48

  1. Reuben A, Tillman H, Fontana RJ, Davern T, McGuire B, Stravitz RT, et al. Outcomes in adults with acute liver failure between 1998 and 2013: an observational cohort study. Ann Intern Med. 2016;164(11):724–32. · DOI · Paper page
  2. • Bjornsson E, Davidsdottir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol. 2009;50(3):511–7. Reports rate of chronic DILI in national (Sweden) hospital database. · DOI · Paper page
  3. Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512–21. · DOI · Paper page
  4. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135(6):1924–1934.e4. · DOI · Paper page
  5. Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology. 2012;55(3):965–7. · DOI · Paper page
  6. European Association for the Study of the Liver. Electronic address eee, Clinical practice guidelines panel, Wendon J, Panel M, Cordoba J, Dhawan A, et al. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017;66(5):1047–81. · DOI · Paper page
  7. Jalan R, Saliba F, Pavesi M, Amoros A, Moreau R, Gines P, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol. 2014;61(5):1038–47. · DOI · Paper page
  8. Gustot T, Fernandez J, Garcia E, Morando F, Caraceni P, Alessandria C, et al. Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology. 2015;62(1):243–52. · DOI · Paper page
  9. Ruhl CE, Everhart JE. Upper limits of normal for alanine aminotransferase activity in the United States population. Hepatology. 2012;55(2):447–54. · DOI
  10. Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut. 1999;44(5):731–5. · DOI · Paper page
  11. Toghill PJ, Smith PG, Benton P, Brown RC, Matthews HL. Methyldopa liver damage. Br Med J. 1974;3(5930):545–8. · DOI
  12. Goldstein GB, Lam KC, Mistilis SP. Drug-induced active chronic hepatitis. Am J Dig Dis. 1973;18(3):177–84. · DOI
  13. Seeff LB. Drug-induced chronic liver disease, with emphasis on chronic active hepatitis. Semin Liver Dis. 1981;1(2):104–15. · DOI
  14. Fontana RJ, Hayashi PH, Gu J, Reddy KR, Barnhart H, Watkins PB, et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology. 2014;147(1):96–108.e4. · DOI · Paper page
  15. •• Fontana RJ, Hayashi PH, Barnhart H, Kleiner DE, Reddy KR, Chalasani N, et al. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury. Am J Gastroenterol. 2015;110(10):1450–9. Reports rate of chronic DILI at 12 months with quality of life data in a U.S. DILI registry. · DOI · Paper page
  16. Zimmerman HJ. Oncotherapeutic and immunosuppressive agents. In: Zimmerman HJ, editor. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lipponcott Williams & Wilkins; 1999. p. 681–7.
  17. Langman G, Hall PM, Todd G. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol. 2001;16(12):1395–401. · DOI · Paper page
  18. Saphner T, Triest-Robertson S, Li H, Holzman P. The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer. Cancer. 2009;115(14):3189–95. · DOI
  19. Mattar W, Juliar B, Gradus-Pizlo I, Kwo PY. Amiodarone hepatotoxicity in the context of the metabolic syndrome and right-sided heart failure. J Gastrointestin Liver Dis. 2009;18(4):419–23.
  20. deLemos AS, Foureau DM, Jacobs C, Ahrens W, Russo MW, Bonkovsky HL. Drug-induced liver injury with autoimmune features. Semin Liver Dis. 2014;34(2):194–204. · DOI
  21. Amacher DE, Chalasani N. Drug-induced hepatic steatosis. Semin Liver Dis. 2014;34(2):205–14. · DOI · Paper page
  22. Reshamwala PA, Kleiner DE, Heller T. Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology. 2006;44(1):7–14. · DOI · Paper page
  23. Ghabril M, Vuppalanchi R. Drug-induced nodular regenerative hyperplasia. Semin Liver Dis. 2014;34(2):240–5. · DOI · Paper page
  24. Carman N, Mack DR, Benchimol EI. Therapeutic drug monitoring in pediatric inflammatory bowel disease. Curr Gastroenterol Rep. 2018;20(5):18. · DOI
  25. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51(6):2193–213. · DOI · Paper page
  26. Angitapalli R, Litwin AM, Kumar PR, Nasser E, Lombardo J, Mashtare T, et al. Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer. Oncology. 2009;76(5):363–8. · doi:10.1159/000210025
  27. Slade JH, Alattar ML, Fogelman DR, Overman MJ, Agarwal A, Maru DM, et al. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer. 2009;8(4):225–30. · doi:10.3816/ccc.2009.n.038
  28. Degott C, Feldmann G, Larrey D, Durand-Schneider AM, Grange D, Machayekhi JP, et al. Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology. 1992;15(2):244–51. · DOI · Paper page
  29. Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, et al. Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis. Hepatology. 1994;20(6):1437–41. · DOI
  30. Olsson R, Wiholm BE, Sand C, Zettergren L, Hultcrantz R, Myrhed M. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol. 1992;15(1–2):154–61. · DOI
  31. •• Bonkovsky HL, Kleiner DE, Gu J, Odin JA, Russo MW, Navarro VM, et al. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology. 2017;65(4):1267–77. Large report of DILI induced vanishing bile duct syndrome and poor outcomes. · DOI · Paper page
  32. Watanabe N, Takashimizu S, Kojima S, Kagawa T, Nishizaki Y, Mine T, et al. Clinical and pathological features of a prolonged type of acute intrahepatic cholestasis. Hepatol Res. 2007;37(8):598–607. · DOI
  33. Chatterjee S, Richert L, Augustijns P, Annaert P. Hepatocyte-based in vitro model for assessment of drug-induced cholestasis. Toxicol Appl Pharmacol. 2014;274(1):124–36. · DOI
  34. Bachour-El Azzi P, Sharanek A, Abdel-Razzak Z, Antherieu S, Al-Attrache H, Savary CC, et al. Impact of inflammation on chlorpromazine-induced cytotoxicity and cholestatic features in HepaRG cells. Drug Metab Dispos. 2014;42(9):1556–66. · DOI
  35. Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015;148(7):1340–52. e7 · DOI · Paper page
  36. Turkish A, Luo JJ, Lefkowitch JH. Ketamine abuse, biliary tract disease, and secondary sclerosing cholangitis. Hepatology. 2013;58(2):825–7. · DOI
  37. •• Gudnason HO, Bjornsson HK, Gardarsdottir M, Thorisson HM, Olafsson S, Bergmann OM, et al. Secondary sclerosing cholangitis in patients with drug-induced liver injury. Dig Liver Dis. 2015;47(6):502–7. Series of DILI induced sclerosing cholangitis reported from an Icelandic DILI registry. · DOI
  38. Horsley-Silva JL, Dow EN, Menias CO, Smith ML, Carballido EM, Lindor KD, et al. Docetaxel induced sclerosing cholangitis. Dig Dis Sci. 2015;60(12):3814–6. · DOI · Paper page
  39. •• Ahmad J, Rossi S, Rodgers SK, Ghabril M, Fontana R, Stolz A, et al. Sclerosing cholangitis like changes on magnetic resonance cholangiography in patients with drug induced liver injury. Clin Gastroenterol Hepatol (in press). Series of DILI induced sclerosing cholangitis reported from a U.S. DILI registry with blinded and systematic MRCP readings.
  40. Gossard AA, Angulo P, Lindor KD. Secondary sclerosing cholangitis: a comparison to primary sclerosing cholangitis. Am J Gastroenterol. 2005;100(6):1330–3. · DOI
  41. Imam MH, Talwalkar JA, Lindor KD. Secondary sclerosing cholangitis: pathogenesis, diagnosis, and management. Clin Liver Dis. 2013;17(2):269–77. · DOI
  42. Dikengil A, Siskind BN, Morse SS, Swedlund A, Bober-Sorcinelli KE, Burrell MI. Sclerosing cholangitis from intraarterial floxuridine. J Clin Gastroenterol. 1986;8(6):690–3. · DOI
  43. Ludwig J, Kim CH, Wiesner RH, Krom RA. Floxuridine-induced sclerosing cholangitis: an ischemic cholangiopathy? Hepatology. 1989;9(2):215–8. · DOI
  44. Schwab GP, Wetscher GJ, Vogl W, Redmond E. Methimazole-induced cholestatic liver injury, mimicking sclerosing cholangitis. Langenbecks Arch Chir. 1996;381(4):225–7. · DOI · Paper page
  45. Seto WK, Ng M, Chan P, Ng IO, Cheung SC, Hung IF, et al. Ketamine-induced cholangiopathy: a case report. Am J Gastroenterol. 2011;106(5):1004–5. · DOI
  46. Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005;42(2):481–9. · DOI · Paper page
  47. Hayashi PH, Fontana RJ. Clinical features, diagnosis, and natural history of drug-induced liver injury. Semin Liver Dis. 2014;34(2):134–44. · DOI
  48. •• Hayashi PH, Rockey DC, Fontana RJ, Tillmann HL, Kaplowitz N, Barnhart HX, et al. Death and liver transplantation within 2 years of onset of drug-induced liver injury. Hepatology. 2017;66(4):1275–85. Report of long-term mortality from DILI in prospectively followed patients. · DOI · Paper page

Cited by

See all 26

Metadata

Authors
Hayashi, P. H., & Bjornsson, E. S.
Venue
Current Hepatology Reports
Published
2018-07-02
Volume
17
Issue
3
Pages
292-299
ISSN
2195-9595
Cited by
26
References
2
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-Term Outcomes After Drug-Induced Liver Injury. https://app.cochat.ai/papers/10.1007/s11901-018-0411-0
The paper
Hayashi, P. H., & Bjornsson, E. S. (2018). Long-Term Outcomes After Drug-Induced Liver Injury. Current Hepatology Reports. https://doi.org/10.1007/s11901-018-0411-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.